← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Axonis Therapeutics, Inc.
Boston, MA
$4,104,648
Total funding
7
Grants
Funding over time
peak $1.7M · FY2020–24$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,788,557 · 6
DOD$316,091 · 1
By mechanism
R44$2,200,694 · 1
R43$1,587,863 · 5
—$316,091 · 1
Investigators at Axonis Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of KCC2 Neuromodulators to Treat Paralysis After Spinal Cord Injury.$1,426,925
R44 · FY2023 · NS
Development of KCC2 neuromodulators to treat paralysis after spinal cord injury.$773,769
R44 · FY2022 · NS
Development of Neuromodulating AAV-KCC2 Gene Therapy to Treat Paralysis, Spasticity and Neuropathic Pain after Spinal Cord Injury$335,668
R43 · FY2022 · NS
Development of KCC2 neuromodulators to treat paralysis after spinal cord injury.$330,619
R43 · FY2020 · NS
Development of Oral KCC2 Potentiator AXN-027 as a Novel Anti-Epileptic Drug for Mesial Temporal Lobe Epilepsy$323,001
R43 · FY2024 · NS
ACCELERATING TRANSLATION OF A SMALL-MOLECULE KCC2 ENHANCER TO PROMOTE RECOVERY AND REDUCE NEUROPATHIC PAIN AFTER SCI USING A PIG MODEL$316,091
· FY2022 · Defense Health Agency
Development of oral KCC2 enhancer drug for treatment of painful diabetic neuropathy$299,756
R43 · FY2023 · DK
Development of AAV-AXN-007 gene therapy to treat glaucoma.$298,819
R43 · FY2022 · EY